Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > From Linkedin

<< Previous

Bullboard Posts

Next >>

Comment by fasttrack5on Jul 20, 2024 12:49am

169 Views

Post# 36140970

RE:RE:From Linkedin

Anticipated Milestones are expected to include:

H1 2024: Guidance on the registration path for HR+/HER2- mBC (metastatic breast cancer)
H1 2024: Initiation of the PanCAN-supported Phase 2 Pancreatic Ductal Adenocarcinoma (PDAC) trial incorporating mFOLFIRINOX +/- atezolizumab and pelareorep
Mid-2024: Initiation of the adaptive Phase 3 trial for pelareorep in PDAC
Overall survival results from the BRACELET-1 study
Expand enrollment following achievement of success criteria from the GOBLET Phase 1/2 study anal cancer cohort